Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study

• Published in: Osteoporosis international 2024-08, Vol.35 (8), p.1407-1415
• Main Authors: Gold, Deborah T., Beckett, Tammy, Deal, Chad, James, Andrew L., Mohseni, Mahshid, McMillan, Abigail, Bailey, Tom, Pearman, Leny, Caminis, John, Wang, Yamei, Williams, Setareh A., Kernaghan, Jacqueline M.
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Assessment of Medication Adherence; Bone Density Conservation Agents - therapeutic use; Drug Costs; Drug use; Endocrinology; Female; Humans; Medical records; Medicine; Medicine & Public Health; Menopause; Middle Aged; Observational studies; Original; Original Article; Orthopedics; Osteoporosis; Osteoporosis, Postmenopausal - drug therapy; Osteoporotic Fractures - prevention & control; Parathyroid Hormone-Related Protein - pharmacology; Parathyroid Hormone-Related Protein - therapeutic use; Patient compliance; Patients; Post-menopause; Practice Patterns, Physicians' - statistics & numerical data; Prescription drugs; Retrospective Studies; Rheumatology; Womens health
• ISSN: 0937-941X; 1433-2965; 1433-2965
• DOI: 10.1007/s00198-024-07070-z

Summary Review of medical records from 173 women with osteoporosis who received abaloparatide treatment revealed that 96.0% had at least one visit for osteoporosis management and 55.5% had medication support group access. The most common reasons for discontinuing treatment were financial (31.2%) and tolerability (22.8%). Most patients (64.8%) completed treatment as prescribed. Purpose Abaloparatide is approved for the treatment of women with postmenopausal osteoporosis at high risk for fracture. This study evaluated real-world treatment patterns for patients new to abaloparatide, regardless of osteoporosis treatment history. Methods Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US. Results A total of 173 patients were enrolled (mean [SD] age, 69.8 [7.4] years). At the time of abaloparatide treatment initiation, 78.6% had received other osteoporosis medications. Mean (SD) time from discontinuation of osteoporosis medications prior to initiation of abaloparatide was 1.7 (3.2) years. Twenty-four months of follow-up data from the initiation date of abaloparatide was collected from 94.0% of patients and 6.0% of patients had 12–24 months of follow-up. During the follow-up period, 96.0% of patients had at least one visit for osteoporosis management and 55.5% had access to a medication support program. The median duration of therapy was 18.6 months and 105/162 (64.8%) completed abaloparatide treatment as prescribed. The most common reasons for treatment discontinuation were financial (31.2%) and tolerability (22.8%). Following completion of a course of treatment with abaloparatide, 82/162 (50.6%) patients transitioned to another osteoporosis medication. The median time between abaloparatide treatment course completion and the initiation of follow-on medication was 21 days. Conclusion Most patients completed treatment with abaloparatide as prescribed, and over half continued with an antiresorptive agent. This favorable conduct may be the result of regular follow-up visits and accessibility to both medication and patient support services.